Our regulatory lawyers have extensive experience advising businesses and individuals regulated by the Medicines and Healthcare products Regulatory Agency (MHRA) on how best to navigate regulatory challenges (see here). 

If you have encountered, or otherwise wish to prepare for, a regulatory difficulty, please contact our team of regulatory lawyers for a confidential and no-obligation initial meeting. 

Activity:

• On 21 and 22 April 2026 we attended the Making & Distributing Pharmaceuticals 2026 conferences to support the exhibition of the Paradigm Shift Group Ltd, and to meet with other clients and experts in the industry. 

• Following Ben Thorogood's presentation at the 2025 UK GDP Association Conference, 'A Litigator's Perspective: When GDP Goes Wrong', Laytons ETL was pleased to attend the UK GDP Association Annual Conference 2026 and share insights surrounding whistleblowing in a pharmaceutical and GDP context.
  
  Joined by Dave Rushton of Paradigm Shift Consulting, Ben’s presentation explored the role of effective reporting procedures and compliance frameworks within the pharmaceutical sector.
  
  Laytons ETL remains committed to supporting the UK GDP Association and its important work across the pharmaceutical industry. To accompany this year's presentation, we have prepared a series of practical whistleblowing guides which are available on request.

Regulatory Difficulty? - Checklist

This checklist is intended to provide businesses and individuals regulated by the MHRA with a practical guide to handing their initial response to a regulatory difficulty.

Please see a PDF version of this table here.

Important note: this checklist provides general guidance only and does not constitute legal advice. Each matter is fact-specific and the best response will depend on the particular circumstances.